Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Clofarabine PET Imaging in Metastatic Cancer
NCT05065736Phase 1Terminated
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-clofarabine in metastatic cancer. Primary endpoint: Evaluation of CFA as a PET imaging agent at 60 minutes. Started Mar 2023; status: terminated.
02
Drugs
18F-clofarabine
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT05065736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065736.